The Patient Ferris Wheel: Centering the Patient in the CGT Supply Chain
At Advanced Therapies Week 2025, Cryoport Systems’ Chief Commercial Officer Aruna Mor and Senior Vice President & Chief Product Development Officer Mike Dybicz took the stage with moderator Patrick Galliot, Sr. Director of Patient Operations at Abeona Therapeutics, to discuss how securing the future of medicine starts with minimizing risk and maximizing patient impact. Their conversation, The Patient Ferris Wheel – Centering the Patient in CGT Supply Chain, explored how Cryoport Systems is driving innovation in shipping systems designed specifically for advanced therapies.
Building a Patient-Centric Supply Chain
Cryoport Systems has spent years refining its approach to temperature-controlled logistics, expanding from a logistics provider into an end-to-end supply chain management platform that integrates BioServices and biostorage, advisory services, and cryopreservation. A key theme of the discussion was the need to design shipping solutions not only for product integrity but also for the realities of clinical sites and end users.
Mike highlighted the evolution of Cryoport Systems’ product development process, emphasizing the importance of working directly with clinical teams, specialty pharmacies, and sponsors to ensure that shipping solutions address real-world challenges. This approach led to innovations such as the Cryoport Express® Cryogenic HV3 shipping system, which enhances patient access by optimizing flight availability, improving mobility, and increasing ease of use for clinicians.
Mitigating Risk Through Innovation
Ensuring the integrity of temperature-sensitive cell and gene therapies is critical when handling irreplaceable materials. Cryoport Systems’ risk mitigation strategy is built on near real-time data monitoring, rigorous requalification processes, and its proprietary Veri-Clean® system, which sets the industry standard for decontamination. The team discussed how leveraging millions of data points allows Cryoport Systems to identify and proactively address potential risks before they impact a patient’s therapy.
As Aruna explained, every step of the supply chain is an opportunity to reduce risk. From monitoring shipping conditions to enhancing packaging solutions that prevent breakage and contamination, Cryoport Systems is dedicated to safeguarding these life-changing therapies.
Collaboration for the Future
A key takeaway from the discussion was the importance of collaboration. Cryoport Systems works closely with therapy developers, clinical sites, and industry partners to ensure that shipping solutions evolve alongside the rapidly advancing CGT landscape. The company’s advisory and consulting services further support clients in navigating regulatory challenges, developing custom packaging, and ensuring seamless transitions from clinical to commercial stages.
As the industry continues to grow, so does the need for reliable, patient-focused supply chain solutions. Cryoport Systems remains committed to working hand in hand with the CGT community to refine and advance logistics solutions that put the patient first.
Learn more about how Cryoport Systems is Enabling the Outcome™ for therapy developers and the patients they serve.